WS
GALT icon

Wedbush Securities’s Galectin Therapeutics GALT Stock Holding History

Wedbush Securities’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,498
Closed -$37K – 1233
2024
Q1 		$37K Hold
15,498
– – ﹤0.01% 1216
2023
Q4 		$26K Hold
15,498
– – ﹤0.01% 1074
2023
Q3 		$30K Hold
15,498
– – ﹤0.01% 1040
2023
Q2 		$22K Hold
15,498
– – ﹤0.01% 1052
2023
Q1 		$33K Sell
15,498
-9,000
-37% -$14.5K ﹤0.01% 1052
2022
Q4 		$28K Sell
24,498
-500
-2% -$666 ﹤0.01% 1029
2022
Q3 		$41K Sell
24,998
-3,000
-11% -$5.61K ﹤0.01% 1012
2022
Q2 		$37K Hold
27,998
– – ﹤0.01% 1044
2022
Q1 		$45K Sell
27,998
-2,000
-7% -$3.87K ﹤0.01% 1078
2021
Q4 		$62K Sell
29,998
-1,000
-3% -$2.85K ﹤0.01% 1150
2021
Q3 		$120K Buy
30,998
+13,000
+72% +$44.1K 0.01% 1117
2021
Q2 		$58K Hold
17,998
– – ﹤0.01% 1144
2021
Q1 		$39K Sell
17,998
-2,500
-12% -$5.6K ﹤0.01% 1066
2020
Q4 		$46K Buy
20,498
+3,000
+17% +$7.87K ﹤0.01% 857
2020
Q3 		$47K Sell
17,498
-3,000
-15% -$8.4K ﹤0.01% 887
2020
Q2 		$63K Hold
20,498
– – 0.01% 892
2020
Q1 		$40K Sell
20,498
-1,000
-5% -$2.43K ﹤0.01% 835
2019
Q4 		$61K Hold
21,498
– – 0.01% 956
2019
Q3 		$79K Sell
21,498
-3,000
-12% -$10.8K 0.01% 914
2019
Q2 		$102K Buy
24,498
+6,500
+36% +$28.1K 0.01% 902
2019
Q1 		$92K Hold
17,998
– – 0.01% 861
2018
Q4 		$62K Hold
17,998
– – 0.01% 784
2018
Q3 		$108K Hold
17,998
– – 0.01% 837
2018
Q2 		$114K Sell
17,998
-18,000
-50% -$87.7K 0.01% 800
2018
Q1 		$171K Buy
35,998
+5,499
+18% +$25.6K 0.02% 706
2017
Q4 		$102K Buy
+30,499
New +$77.1K 0.01% 786

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Wedbush Securities's GALT Position: Q2 2024 in Review

Wedbush Securities sold out of Galectin Therapeutics (GALT) in Q2 2024, closing a stake of 15,498 shares — an estimated $37K sold.

Wedbush Securities first reported a position in GALT in Q4 2017 and held it in 26 quarters. The position peaked at $171K in Q1 2018. 73 funds tracked by Wall St. Rank hold GALT as of Q2 2024.

  • Wedbush Securities reported no remaining Galectin Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Wedbush Securities sold 15,498 Galectin Therapeutics shares in Q2 2024, an estimated $37K.
  • Wedbush Securities first reported a position in Galectin Therapeutics in Q4 2017 and held it in 26 quarters.
  • Wedbush Securities's Galectin Therapeutics position peaked at $171K in Q1 2018.
  • 73 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2024.

Based on Wedbush Securities's 13F filing for Q2 2024, filed 7 Aug 2024.